University of Hertfordshire

Dermal and transdermal drug delivery systems: Current and future prospects

Research output: Contribution to journalLiterature review

Standard

Dermal and transdermal drug delivery systems : Current and future prospects. / Brown, Marc; Martin, Gary P. ; Jones, S. A.; Akomeah, F. K.

In: Journal of Drug Delivery Science and Technology, Vol. 13, No. 3, 2006, p. 175-187.

Research output: Contribution to journalLiterature review

Harvard

APA

Vancouver

Author

Brown, Marc ; Martin, Gary P. ; Jones, S. A. ; Akomeah, F. K. / Dermal and transdermal drug delivery systems : Current and future prospects. In: Journal of Drug Delivery Science and Technology. 2006 ; Vol. 13, No. 3. pp. 175-187.

Bibtex

@article{fd4f0f6c8992464c82ecebe8eaa6f7bd,
title = "Dermal and transdermal drug delivery systems: Current and future prospects",
abstract = "The protective function of human skin imposes physicochemical limitations to the type of permeant that can traverse the barrier. For a drug to be delivered passively via the skin it needs to have adequate lipophilicity and also a molecular weight < 500 Da. These requirements have limited the number of commercially available products based on transdermal or dermal delivery. Various strategies have emerged over recent years to optimize delivery and these can be categorized into passive and active methods. The passive approach entails the optimization of formulation or drug carrying vehicle to increase skin permeability. Passive methods, however do not greatly improve the permeation of drugs with molecular weights > 500 Da. In contrast active methods that normally involve physical or mechanical methods of enhancing delivery have been shown to be generally superior. Improved delivery has been shown for drugs of differing lipophilicity and molecular weight including proteins, peptides, and oligonucletides using electrical methods ( iontophoresis, electroporation), mechanical ( abrasion, ablation, perforation), and other energy- related techniques such as ultrasound and needless injection. However, for these novel delivery methods to succeed and compete with those already on the market, the prime issues that require consideration include device design and safety, efficacy, ease of handling, and cost- effectiveness. This article provides a detailed review of the next generation of active delivery technologies.",
keywords = "dermal, drug delivery, permeability, skin, transdermal, HORMONE REPLACEMENT THERAPY, LOW-FREQUENCY SONOPHORESIS, SKIN-BARRIER FUNCTION, IN-VIVO, PERCUTANEOUS-ABSORPTION, ELECTROTRANSPORT SYSTEM, HYDROPHILIC DRUGS, CONTROLLED HEAT, MINI-EROSION, IONTOPHORESIS",
author = "Marc Brown and Martin, {Gary P.} and Jones, {S. A.} and Akomeah, {F. K.}",
year = "2006",
doi = "10.1080/10717540500455975",
language = "English",
volume = "13",
pages = "175--187",
journal = "Journal of Drug Delivery Science and Technology",
issn = "1773-2247",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Dermal and transdermal drug delivery systems

T2 - Current and future prospects

AU - Brown, Marc

AU - Martin, Gary P.

AU - Jones, S. A.

AU - Akomeah, F. K.

PY - 2006

Y1 - 2006

N2 - The protective function of human skin imposes physicochemical limitations to the type of permeant that can traverse the barrier. For a drug to be delivered passively via the skin it needs to have adequate lipophilicity and also a molecular weight < 500 Da. These requirements have limited the number of commercially available products based on transdermal or dermal delivery. Various strategies have emerged over recent years to optimize delivery and these can be categorized into passive and active methods. The passive approach entails the optimization of formulation or drug carrying vehicle to increase skin permeability. Passive methods, however do not greatly improve the permeation of drugs with molecular weights > 500 Da. In contrast active methods that normally involve physical or mechanical methods of enhancing delivery have been shown to be generally superior. Improved delivery has been shown for drugs of differing lipophilicity and molecular weight including proteins, peptides, and oligonucletides using electrical methods ( iontophoresis, electroporation), mechanical ( abrasion, ablation, perforation), and other energy- related techniques such as ultrasound and needless injection. However, for these novel delivery methods to succeed and compete with those already on the market, the prime issues that require consideration include device design and safety, efficacy, ease of handling, and cost- effectiveness. This article provides a detailed review of the next generation of active delivery technologies.

AB - The protective function of human skin imposes physicochemical limitations to the type of permeant that can traverse the barrier. For a drug to be delivered passively via the skin it needs to have adequate lipophilicity and also a molecular weight < 500 Da. These requirements have limited the number of commercially available products based on transdermal or dermal delivery. Various strategies have emerged over recent years to optimize delivery and these can be categorized into passive and active methods. The passive approach entails the optimization of formulation or drug carrying vehicle to increase skin permeability. Passive methods, however do not greatly improve the permeation of drugs with molecular weights > 500 Da. In contrast active methods that normally involve physical or mechanical methods of enhancing delivery have been shown to be generally superior. Improved delivery has been shown for drugs of differing lipophilicity and molecular weight including proteins, peptides, and oligonucletides using electrical methods ( iontophoresis, electroporation), mechanical ( abrasion, ablation, perforation), and other energy- related techniques such as ultrasound and needless injection. However, for these novel delivery methods to succeed and compete with those already on the market, the prime issues that require consideration include device design and safety, efficacy, ease of handling, and cost- effectiveness. This article provides a detailed review of the next generation of active delivery technologies.

KW - dermal

KW - drug delivery

KW - permeability

KW - skin

KW - transdermal

KW - HORMONE REPLACEMENT THERAPY

KW - LOW-FREQUENCY SONOPHORESIS

KW - SKIN-BARRIER FUNCTION

KW - IN-VIVO

KW - PERCUTANEOUS-ABSORPTION

KW - ELECTROTRANSPORT SYSTEM

KW - HYDROPHILIC DRUGS

KW - CONTROLLED HEAT

KW - MINI-EROSION

KW - IONTOPHORESIS

U2 - 10.1080/10717540500455975

DO - 10.1080/10717540500455975

M3 - Literature review

VL - 13

SP - 175

EP - 187

JO - Journal of Drug Delivery Science and Technology

JF - Journal of Drug Delivery Science and Technology

SN - 1773-2247

IS - 3

ER -